{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=39", "query": { "intervention": "Matching Oral Placebo", "page": 39 }, "page_size": 10 }, "pagination": { "page": 39, "page_size": 10, "total_count": 3459, "total_pages": 346, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=40&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=38&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T14:38:07.269Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02706834", "title": "Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dose Finding Study" ], "interventions": [ { "name": "TAK-828", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2016-03-01", "completion_date": "2016-06-17", "has_results": true, "last_update_posted_date": "2018-10-19", "last_synced_at": "2026-10-16T14:38:07.269Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Austin, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706834" }, { "nct_id": "NCT01968031", "title": "A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Parkinson's Disease" ], "interventions": [ { "name": "Istradefylline 40 mg", "type": "DRUG" }, { "name": "Istradefylline 20 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 613, "start_date": "2013-10", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-16T14:38:07.269Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01968031" }, { "nct_id": "NCT03428945", "title": "Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type1 Diabetes Mellitus" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 273, "start_date": "2018-08-15", "completion_date": "2022-10-31", "has_results": true, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-10-16T14:38:07.269Z", "location_count": 37, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 33 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428945" }, { "nct_id": "NCT01359930", "title": "Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Methamphetamine Dependence" ], "interventions": [ { "name": "placebo", "type": "OTHER" }, { "name": "Naltrexone and Bupropion SR", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Institute on Drug Abuse (NIDA)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "21 Years to 50 Years" }, "enrollment_count": 16, "start_date": "2011-08", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2017-01-12", "last_synced_at": "2026-10-16T14:38:07.269Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01359930" }, { "nct_id": "NCT03777657", "title": "Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric, or Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 997, "start_date": "2018-12-13", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-10-16T14:38:07.269Z", "location_count": 6, "location_summary": "Sacramento, California • Newnan, Georgia • Columbus, Ohio + 3 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "West Reading", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03777657" }, { "nct_id": "NCT05050136", "title": "A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cholangitis", "PBC" ], "interventions": [ { "name": "Volixibat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirum Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2021-09-22", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-16T14:38:07.269Z", "location_count": 44, "location_summary": "Coronado, California • Los Angeles, California • Sacramento, California + 38 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05050136" }, { "nct_id": "NCT02372799", "title": "Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Vilazodone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fluoxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "7 Years to 17 Years" }, "enrollment_count": 473, "start_date": "2015-02-28", "completion_date": "2018-09-11", "has_results": true, "last_update_posted_date": "2019-10-01", "last_synced_at": "2026-10-16T14:38:07.269Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02372799" }, { "nct_id": "NCT00325572", "title": "Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autism", "Pervasive Developmental Disorder" ], "interventions": [ { "name": "oral zinc and vitamin C supplements", "type": "DRUG" }, { "name": "oral Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "3 Years", "maximum_age": "8 Years", "sex": "ALL", "summary": "3 Years to 8 Years" }, "enrollment_count": 89, "start_date": "2006-11", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2019-07-17", "last_synced_at": "2026-10-16T14:38:07.269Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00325572" }, { "nct_id": "NCT03355209", "title": "A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lennox Gastaut Syndrome" ], "interventions": [ { "name": "ZX008 0.2 or 0.8 mg/kg/day", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "2 Years to 35 Years" }, "enrollment_count": 296, "start_date": "2017-11-27", "completion_date": "2024-05-23", "has_results": true, "last_update_posted_date": "2025-07-03", "last_synced_at": "2026-10-16T14:38:07.269Z", "location_count": 30, "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03355209" }, { "nct_id": "NCT01929863", "title": "Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "GSK2330672", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "30 Years to 64 Years" }, "enrollment_count": 16, "start_date": "2013-08-01", "completion_date": "2013-11-21", "has_results": true, "last_update_posted_date": "2017-08-16", "last_synced_at": "2026-10-16T14:38:07.269Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01929863" } ] }